Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease

In this phase 2 study, preladenant used as adjunctive therapy in PD patients on stable doses of levodopa did not reduce mean OFF time; treatment was well tolerated at doses between 2 and 10 mg BID.